WatsHot in the Small-Cap Market: Omega Diagnostics, Motif Bio, RedX Pharma and Minds+Machines
This morning we were treated to good news from Omega Diagnostics* (ODX), who confirmed that they have resolved the manufacturing variability issues with Visitect CD4, their point-of-care test for assessing the levels of CD4 in the blood (which indicates when to start treatment for HIV). The firm said it has now made three pilot batches…